Cita APA (7a ed.)
Schroeder, B. A., Mandelson, M. T., & Picozzi, V. J. (2023). Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect. Cancers, 15(23), 5588-5598.
Cita Chicago Style (17a ed.)
Schroeder, Brett A., Margaret T. Mandelson, y Vincent J. Picozzi. "Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect." Cancers 15, no. 23 (2023): 5588-5598.
Cita MLA (9a ed.)
Schroeder, Brett A., et al. "Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect." Cancers, vol. 15, no. 23, 2023, pp. 5588-5598.
Precaución: Estas citas no son 100% exactas.